摘要
目的探究分析利拉鲁肽在2型糖尿病合并肥胖患者对胰岛素抵抗中应用的临床效果及护理体会。方法选取70例2型糖尿病合并肥胖患者随机分为两组各35例,试验组给予利拉鲁肽治疗,对照组给予常规胰岛素治疗,两组均给予健康教育指导并加强专科护理。对比治疗6个月、1.5年两组患者胰岛素抵抗的差异情况。结果两组患者治疗后血糖和胰岛功能指标和体质量指标(BMI)均有所下降,其中试验组治疗6个月上述水平明显低于治疗前(P<0.05),而对照组治疗1.5年血糖、胰岛功能和体质量指标明显低于治疗前(P<0.05),全部患者HOMA-β,高密度脂蛋白-胆固醇HDL-C有所上升,其中试验组治疗6个月上述指标明显高于治疗前(P<0.05),对照组治疗1.5年HOMA-β明显高于治疗前(P<0.01),观察组治疗6个月、1.5年上述指标均显著优于对照组,比较差异具有显著性(P<0.01)。结论利拉鲁肽治疗糖尿病合并肥胖患者的临床疗效显著,配合可靠的护理,可有效降低体质量并改善血糖水平,且临床安全性高。
Objective Our retrospective study was aimed to explore and analyze the efficacy of Liraglutide in treating insulin resistance of patients who had type2 diabetes and obesity and the nursing experiences.Methods 70 cases with type 2 diabetes and obesity were divided into two groups according to the random number table,the experimental group and the control group,35 cases in each group. The patients in the experimental group were treated with Liraglutide. The patients in the control group were treated with routine insulin treatment. All the patients were given health education guidance and strengthening nursing. Compared the insulin resistance of the two groups at the time points 6 months and 1.5years after treatment.Results The blood glucose,pancreas function indicators,BMI of the two groups had decreased. Six 6 months after treatment,the level of blood glucose,pancreas function indicators and BMI in experimental group statistically significant lower than those before（ P〈0. 05）,while 1. 5yearss after treatment the levels of those indicators of control group statistically significant lower than those before（ P〈0.01）. HOMA-β and HDL-C concentration of all patients had increased.Six 6 months after treatment,the level of HOMA- β and HDL- C in experimental group statistically significant lower than those before the treatment,and 1. 5years after treatment the level of HOMA- β in control group statistically significant higher than that before（ P〈0. 01）. No matter 6 months or 1. 5 years after treatment the HOMA- β and HDL- C concentration of experimental group were statistically significant higher than those in control group（ P〈0. 05）. Conclusions Liraglutide can receive an ideal effect in treating type 2 diabetes and obesity patients,cooperate with reliable nursing,it also can improve blood sugar levels and BMI,with ideal clinical safety.
出处
《齐齐哈尔医学院学报》
2016年第27期3457-3460,共4页
Journal of Qiqihar Medical University
基金
东莞市科技局科研项目立项编号:2015105101163
